Thus, the evaluation of sGRP78+CXCR4+ markers along with CD10 and CD19 in leukemic pediatric samples at diagnosis could contribute to a better categorization of High and Standard-risk pediatric leukemia. This evidence concerns the gene CD19 and leukemia.